Last $0.61 USD
Change Today +0.0079 / 1.31%
Volume 512.8K
As of 8:10 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.62
Previous Close
$0.60
Day High
$0.63
Day Low
$0.60
52 Week High
03/5/14 - $0.97
52 Week Low
10/1/13 - $0.24
Market Cap
148.8M
Average Volume 10 Days
1.0M
EPS TTM
$-0.06
Shares Outstanding
244.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a drug-medical device and therapeutic company, designs, develops, and commercializes medical approaches for the treatment of solid tumors in the United States. The company is developing technology based on the proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Its clinical programs include three Phase II clinical trials to assess the cancer-destroying and tissue-sparing properties of the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. The company was formerly known as NetVentory Solutions, Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

12 Employees
Last Reported Date: 12/10/13

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $390.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $247.2K
Compensation as of Fiscal Year 2013.

oncosec medical inc (ONCS) Key Developments

OncoSec Medical Announces Positive Interim Data from Phase II Melanoma Study

OncoSec Medical Inc. has announced positive interim data from a Phase II study of ImmunoPulse in patients with advanced melanoma. Data from the multicenter, open-label, single-arm study confirmed the safety of OncoSec's lead product candidate, ImmunoPulse, which delivers the anti-tumor agent pIL-12 directly into the tumor via in-vivo electroporation (EP), with no treatment-related serious adverse events or deaths having been reported. Regression of treated and non-treated tumors suggests successful induction of systemic anti-tumor response. To date, 30 patients have been enrolled and have received at least one cycle of treatment. At the time of this interim analysis, 28 patients were evaluable for objective response rate (ORR) at 24-week primary time point.

OncoSec Medical Inc. Appoints Dr. Soldano Ferrone to Scientific Advisory Board

OncoSec Medical Inc. has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.

OncoSec Medical Incorporated Presents at BIO International Convention, Jun-25-2014 02:45 PM

OncoSec Medical Incorporated Presents at BIO International Convention, Jun-25-2014 02:45 PM. Venue: San Diego Convention Center, San Diego, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.61 USD +0.0079

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.